Interpace Diagnostics Group has introduced a new version of its AccuCEA product dubbed Insights for pancreatic cancer testing.
The AccuCEA Insights service offers physicians for whom the firm has already provided first line testing with additional information to compare results against other patients in its database of over 15,000 patients.
It enables physicians to know about the patient's potential molecular profile and overall risk for developing pancreatic cancer.
Based on the report, the physician will conduct molecular pathology review using PancraGen pancreatic cyst molecular test.
PancraGen will consider all the results from first line testing, imaging, cytology, and molecular testing and stratifies the patient in one of four risk categories.
PancraGEN uses a small sample of pancreatic cyst fluid for the assessment of pancreatic cancer risk.
Interpace Diagnostics president and CEO Jack Stover said: "The additional information provided via AccuCEA Insights provides physicians a more expansive view of their patient's status and enables them to make an informed decision regarding the most appropriate next steps.
"We believe customers who currently order first line testing services only will see the value in not only the incremental information provided via AccuCEA Insights but the full benefits of our fully integrated molecular product, PancraGEN."
Interpace Diagnostics offers molecular diagnostic tests and pathology services for assessing risk of cancer.